New drug - Volibris
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Cl... Read more
This time last year, Gordon Brown was still riding high in the opinion polls after a successful star... Read more
Practices have been affected by a raft of reforms and restructures that successive governments have ... Read more
When the quality framework was first conceived it was intended to improve outcomes for patients, par... Read more
Two years ago the GPC drew up a shortlist of its negotiating priorities. GP has used this as the bas... Read more
NHS spending was £35 billion when Labour came into power in 1997. By 2010/11 it is expected to reach... Read more
GP understands that health secretary Alan Johnson will not be attending week's LMCs conference. This... Read more
In the increasingly convoluted debate about Darzi reforms and 'polyclinics', GPs tend to be cast as ... Read more
In a spectacular U-turn NICE has backtracked on its recommendations for cardiovascular risk assessme... Read more
General practice is no longer a one-size fits all profession. It may have been the case at the found... Read more
A supertanker is often described as slow to turn, but compared with changing minds in the DoH it cor... Read more
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Cl... Read more
Thymoglobuline is an immunosuppressant for the prophylaxis of graft rejection in renal or heart tra... Read more
Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option... Read more